As 5 more biotechs file their IPOs, one Nasdaq official doesn't see momentum slowing down anytime soon
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
It’s been a heck of a ride for the biotech IPO market over the last year and a half, with 2020 setting record figures and 2021 on track to reach even greater heights. And as another five biopharmas filed their S-1s late Friday, one expert doesn’t see a slowdown occurring any time soon.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.